Beacon Pharmaceuticals PLC is listed on the Dhaka Stock Exchange under the ticker BEACONPHAR. This page carries the price history chart for BEACONPHAR and lets you practice buying and selling it with virtual money, under the same trading hours, settlement delay and commission the real market applies.
Chart data is derived from the published Dhaka Stock Exchange day-end archive. It can lag or contain gaps and should never be treated as an official quote.
Audited financial ratios and DSE exchange disclosures for BEACONPHAR
Official Price Sensitive Information (PSI) and filings for BEACONPHAR
Hold BEACONPHAR in your portfolio?
Boss Tier subscribers get access to the Portfolio News Radar, automatically scanning all active holdings and highlighting critical dividend declarations and PSI updates.
Upgrade to Boss (৳20/mo)The company has requested the Shareholders to update their respective BO account with 12 digits e-TIN number, BO account, address, mobile number, e-mail address etc. through their respective DPs before the Record Date.
The company hereby informs its shareholders and stakeholders that the Company will make an investment of BDT 250 crore in oncology production facility 2. Upon completion, annual production capacity will increase by 37.97 crore tablets, 21.10 crore capsules, 2.53 crore blisters and 2 crore vials injectable. The investment is expected to have a positive impact on the Company's revenue. (cont.) (Cont. News of BEACONPHAR): The Company will strengthen its R&D capabilities to enhance the regulatory readiness of its own drugs for SRA markets. Through rigorous research, product optimization and compliance with international quality standards, the Company will prepare its products for stringent regulatory assessment and approval. (end)
There will be no price limit on the trading of the shares of the Company today (17.10.2026) following its corporate declaration.
The Board of Directors has recommended 11% Cash Dividend for the year ended June 30, 2026. Date of AGM: 13.12.2026, Time: 11:00 AM, Venue: Digital Platform subject to approval from BSEC. Record Date: 10.11.2026. The Company has also reported EPS of Tk. 8.41, NAV per share of Tk. 35.83 and NOCFPS of Tk. 9.68 for the year ended June 30, 2026 as against Tk. 4.10, Tk. 28.86 and Tk. 6.93 respectively for the year ended June 30, 2025. (cont.1) (Cont. News of BEACONPHAR): EPS, NAV & NOCFPS: For the year ended 30 June 2026, the audited financial statements of Beacon Pharmaceuticals PLC show earnings per share (EPS) more than doubling to BDT 8.41 from BDT 4.10 (+105.19%), driven mainly by 30.96% higher sales. (cont.2) (Cont. News of BEACONPHAR): Net asset value (NAV) per share rose 24.14% to BDT 35.83 from BDT 28.86, as retained earnings strengthened shareholders' equity. Net operating cash flow per share (NOCFPS) increased 39.76% to BDT 9.68 from BDT 6.93, on higher receipts from customers and others. (end)
As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on October 15, 2026 at 3:30 PM to consider, among others, audited financial statements of the Company for the year ended June 30, 2026.
The company has informed that Mr. Anindya Sarkar FCS has been appointed as the Company Secretary of the Company with effect from 01.09.2026.
The Company has informed that Mr. Md. Emroj Hossain will hold the Current Charge of the responsibilities of Company Secretary of the company with effect from July 01, 2026.
(Q3 Un-audited): EPS was Tk. 1.22 for January-March 2026 as against Tk. 0.28 for January-March 2025; EPS was Tk. 5.95 for July 2025-March 2026 as against Tk. 3.75 for July 2024-March 2025. NOCFPS was Tk. 9.45 for July 2025-March 2026 as against Tk. 5.45 for July 2024-March 2025. NAV per share was Tk. 33.55 as on March 31, 2026 and Tk. 28.86 as on June 30, 2025. (cont.) (Cont. News of BEACONPHAR): Reasons for deviation: Revenue growth in the prior year was constrained due to socio-political factors, which also impacted operating cash flows. However, in the current year's third quarter, the company has recovered and achieved strong revenue growth. As a result, improved cash collections have led to a notable increase in NOCFPS, reflecting better operational performance and liquidity compared to the same period last year. (end)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on April 27, 2026 at 3:00 pm to consider, among others, Un-Audited Financial Statements for the Third Quarter (Q3) period ended March 31, 2026.
(Q2 Un-audited): EPS was Tk. 2.47 for October-December 2025 as against Tk. 1.91 for October-December 2024; EPS was Tk. 4.73 for July-December 2025 as against Tk. 3.47 for July-December 2024. NOCFPS was Tk. 6.57 for July-December 2025 as against Tk. 6.38 for July-December 2024. NAV per share was Tk. 32.32 as on December 31, 2025 and Tk. 28.86 as on June 30, 2025.
Nothing is loosened to make practice easier. An order for BEACONPHAR is accepted only while the Dhaka Stock Exchange is open, commission is deducted the way a broker would deduct it, and shares cannot be sold until they have settled: two trading days after purchase for categories A, B, G and N, three for category Z.
This is an ordinary equity listing on the Dhaka Stock Exchange. Buying a share means owning a small stake in the business, and the share price responds to earnings, dividends, sector conditions and overall market sentiment.
Ordinary shares are the most straightforward instrument to learn on, which is why most people start here before touching funds or bonds.
Audited financial ratios, annual EPS, NAVPS, 52-week price range and dividend history for BEACONPHAR are published above. For external community discussions or alternative screener tools, you can also inspect BEACONPHAR on third-party market sites.
We do not use StockNow data, and this link is neither sponsored nor affiliated.
View BEACONPHAR on StockNowWe are not responsible for the content of that site or for anything you do there.
Test an idea on BEACONPHAR with virtual money in the full trading terminal, alongside the rest of your practice portfolio.
Open the trading terminalBeacon Pharmaceuticals PLC trades on the Dhaka Stock Exchange under the ticker BEACONPHAR (PharmaChem sector, Category A, listed in 2010). You use that symbol to look the company up on the exchange, with a broker, or inside the StockSimulatorBD practice terminal.
According to Dhaka Stock Exchange disclosures published on this StockSimulatorBD page, BEACONPHAR has a reference share price of ৳89.8, audited P/E ratio of 21.83, annual EPS of ৳4.10, NAVPS (book value) of ৳28.86, dividend yield of 1.98%, 52-week trading range of ৳87.6 to ৳117.9. In 2025, BEACONPHAR declared 21% cash dividend.
Yes. StockSimulatorBD lets you buy and sell BEACONPHAR using a virtual balance. Orders follow the same rules the real market applies, including authentic DSE trading hours (10:00 to 14:15 BST), T+2/T+3 settlement lots (by market category) and a 0.40% commission, but no real money is ever involved and the balance cannot be withdrawn.
No. A BO (Beneficiary Owner) account with a licensed broker is required to buy BEACONPHAR for real on the Dhaka Stock Exchange, but not to practice on StockSimulatorBD. Many investors audit company fundamentals and rehearse trades here before opening a broker account.
The Dhaka Stock Exchange trades Sunday to Thursday from 10:00 to 14:15 Bangladesh Standard Time (BST) and is closed on Friday, Saturday and public holidays. The simulator enforces the same schedule, so BEACONPHAR orders are only accepted while the real market is open.